Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data provide valuable insights for everyday practice. A long-term goal of systemic psoriasis therapy is to erase the inflammatory memory and thus achieve a sustainable cure. Several research projects have therefore focused on tissue-resident memory T-cells.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people
Benefit of the high-dose influenza vaccine
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Artificial intelligence